Estrogen Actions in Triple-Negative Breast Cancer.
Oliver TreeckSusanne Schüler-ToprakOlaf OrtmannPublished in: Cells (2020)
Triple-negative breast cancer (TNBC) lacks estrogen receptor (ER) α, but the expression of estrogen receptors ERβ and G protein-coupled estrogen receptor 1 (GPER-1) is able to trigger estrogen-responsivity in TNBC. Estrogen signaling in TNBC can also be activated and modulated by the constitutively active estrogen-related receptors (ERRs). In this review article, we discuss the role of ERβ and GPER-1 as mediators of E2 action in TNBC as well as the function of ERRs as activators and modulators of estrogen signaling in this cancer entity. For this purpose, original research articles on estrogen actions in TNBC were considered, which are listed in the PubMed database. Additionally, we performed meta-analyses of publicly accessible integrated gene expression and survival data to elucidate the association of ERβ, GPER-1, and ERR expression levels in TNBC with survival. Finally, options for endocrine therapy strategies for TNBC were discussed.
Keyphrases
- estrogen receptor
- gene expression
- poor prognosis
- systematic review
- dna methylation
- randomized controlled trial
- meta analyses
- stem cells
- squamous cell carcinoma
- papillary thyroid
- mesenchymal stem cells
- young adults
- electronic health record
- cell therapy
- long non coding rna
- bone marrow
- artificial intelligence
- lymph node metastasis